Soybean oligosaccharides strong resistance, will become the new food ingredients

Jhonggua maturity and study the impact of cultural type oligosaccharide content of soybean seeds are rich in non-digestible galactooligosaccharides (GOS). Thus, commercial mature seeds of two soybean cultivars (yellow) and two green soybean seed (not mature) should be green soybean seed from intensive farming, and should be green soybean seed biological growth. carbohydrate (low molecular weight, LMWC) as a drug carrier in the soybean seeds with 85% ethanol and determined by spectrophotometry and high performance liquid Chromatography major soybean seed cloud liquid water distribution: stachyose, raffinose and sucrose oligosaccharides showed no significant effect, by biological or intensive culture techniques contrary, but in accordance with the maturity of GOS content found soybean seeds. Soybean seeds, yellow Show Advanced oligosaccharide content (1.84 - 1.95%), compared with immature green seeds (1.43 - 1.61% Other grain content by maturity, thus making the relative percentage, immature, GOS (47 - 53% ) Mature (21 more than the soybean seed -. 34%) In addition, purify soybean GOS higher biological growth of soybean seeds yellow GOS content and methods have been reported, although it contains GOS choice been enriched, the resulting yield is low and effective purification has not been well implemented. Based on these results, yellow soybean seeds seem to be a good source, but GOS, in order to improve their purification, simple methods in medical colleges will be further development and evaluation.

Something you want to know Pharmaceutical Chemicals Syringa vulgaris

Product name:Syringa vulgaris
CAS: 118-34-3
Molecular Formula:C17H24O9
Molecular Weight: 372.3671
Product description:Bleeding, Syringa vulgaris is a kind of strong toxic liver drug resistance, with recovery microsomal enzyme system of enzyme activity and inhibition of lipid peroxidation, can promote the metabolism of liver poison, and improve liver function, make its normalization.

See here for more information:Buy Syringa vulgaris


 Syringa vulgaris, commonly known as the common lilac, erect, more stems, suckering, Bush is in a mature olive family usually 12-16 "(20 ') high, wide and 8-12 spread" (15'). It comes from the forests, rocky hills and jungle region in south-eastern Europe open, but in the whole of Europe (beginning in the late 16th century) and is widely used in North America (in the early 17th century brought colonists) cultivation. Very fragrant, tubular with its unique mid to late spring (May) bloom mentioned, 4-lobed, lilac purple flowers (including 1/3 "long), the narrowing of the large pyramidal panicles (6-8 bloom "long). Took a road cluster smooth, brown, crushed, cracked seed capsules (with a maximum of 3/4 "long), in the winter to do, if not eliminate clothing. Frost, on the contrary, pointed-ovate to heart-shaped leaves (2 -5 "long) as a dark gray-green to blue-green. No autumn colors. Bark is gray to gray-brown.

Doctors freelance can "cure"

After the medical service capacity and market demand huge gap widening, the Chinese health care system is facing a huge change in the situation. Under this change in the situation, change the health care industry is the trend, but in the end where to start priority to promote the eyes of the beholder, the wise see wisdom.
In the health insurance fund increasingly tight financial subsidies can not be a large-scale promotion of the status quo, to control medical expenses become the first choice policy, whether it is implemented for many years in a variety of drug prices bidding and suppress acts of drug prices, or the recently pushing the grading clinic , all from different angles in order to control medical costs. But the drugs to support medical system can not be truly effective to control the medical practices of doctors, will not be able to implement drug price control. The three patients still preferred in many cases, resulting in the rapid growth of medical expenses. This is the main reason is the patient's trust issues, even though a clear precondition for the top three restrictions on the policy, the business volume of the top three is still growing year by year and accounted for in the overall diagnosis times increased year by year.
Therefore, the current market on how to promote medical control expenses form some consensus, cancel drug addition, at the right time might peel outpatient pharmacy, strengthen more practice until the transition to freelance. On drug prices in question, as long as the policy really determined to drugs to support medical system will eventually be neutralized. But on the question of the freedom of practicing physicians, especially the freedom to practice can really promote quality resources in order to stimulate the sinking costs of medical control problems, the current situation is still difficult to be optimistic.
First, the existing health care system restricts freedom of practicing physicians. In the current health care system, doctors mainly from its level of income and business volume in which, while the patient see a doctor more attention titles and abilities. Therefore, even if the title is not high, but some doctors ability, business acceptance of their own is still limited to large hospitals. In reality the situation had low levels of a large hospital doctors more practice the occurrence of cold, its very popular with users in the major hospitals welcome, but more practice to place but deserted. This indicates that the current health care system more "not recognize recognize only the Temple monk." In this case, the development of more practice could only make those high titles of a few experts to play a role in a large number of junior doctors still can not get recognized by the market development of the business, let alone get them out of their own free practice.
Furthermore, the need for freedom to practice good national or at least regional medical services payment standards and norms, this allows the doctor can be determined according to the standard price. Now mainly rely on Medicare to develop a model has set pricing system, but the price is determined by this system of medical services is too low, the doctor will be restricted only to return to profit by the old product, which is returned to the current large public hospitals urgently needed get rid of the road, on the whole not only can not solve the current problem of controlling costs, but may be further aggravated. This is because the current health regulatory system is not perfect, can not effectively to monitor the behavior of medical problems.
Secondly, the freedom to practice or can not solve the problem of shortage of qualified doctors. The current shortage of qualified doctors, but every year a large number of high-quality graduate medical students are not engaged in medical work, mainly because the employment needs of large hospitals have is not strong, and the grassroots low incomes, few people are willing to go. On the one hand, the market demand is huge, patients flock to three hospitals, on the one hand, the grassroots insufficient supply of qualified doctors, patient demand can not be met. This is mainly caused by the payment system problem. Due mainly rely on grassroots consultation fee, but health care system limits the increase consultation fees, which led doctors revenue still can not get promoted, but also limits its ability to attract qualified doctors.
Finally, the pursuit of personal values ​​also limits doctors to start practicing freedom. Chinese concept of health education is the long-standing good doctor in the top three, only the poor academic performance before going to the grassroots level. Under the guidance of this concept, to the exclusion of their own doctor first to go grass roots, not to mention to the grass roots also get a decent income and respect. In such a situation, the patient did not dare to believe more grassroots doctors, patients would think the grassroots doctors are not capable people, or how the work will not three. This is generally caused by a vicious cycle, and also restricting the transformation of the health care system.

Buy amlodipine sources of supply

About Produts:
Product name:Amlodipine
CAS: 111470-99-6
Molecular Formula: C26H31ClN2O8S
Molecular Weight: 567.05
Product description:Antihypertensive drugs, are two hydrogen pyridine class calcium antagonists (calcium antagonists or slow channel blockers | | selective calcium channel blockers | | the prevention and treatment of angina pectoris medicine | | blood pressure medications), the blood vessels are strong selectivity, but diastolic coronary blood vessels and blood vessels, increase coronary blood flow, lower blood pressure.


From: http://www.chemicalspharm.com/products/Herb-Extract/Amlodipine-/

Pfizer mode being questioned

Today, well-known pharmaceutical analyst Bernard Munos questioned Pfizer rely on acquisitions to sustain growth of the business model in Forbes's column. Although repeated acquisitions greatly increase sales, but the net profit increase is limited. Pfizer, the market value of 120 billion in 2000, and now 200 billion, and McDonald's burger price growth rate almost. While shareholders get $ 95 billion in dividends, but Pfizer stock is now lower than in 1999 (of course, when there is a bubble biopharmaceuticals). He believes that patients decrease the use of innovative drugs is the main pressure of the whole industry growth, of course, are the same for all pharmaceutical companies. The key to survival is to improve the patient's unit profit, but price increases have been limited by space. He said Pfizer has talent, courage, have the resources, do not need to transfer the headquarters of such means of tax avoidance

Progress in the field of AIDS research breakthrough year 2015

Currently, there are 35 million people worldwide living with HIV, the majority of people who need AIDS drugs did not conditions for treatment. 2001 3.4 million new global HIV infections, and 2013 new cases decreased 38 percent, to 210 million; 75% of those infected are mainly concentrated in 15 countries, such as in sub-Saharan Africa, Nigeria, the number of new HIV infections in South Africa and Uganda, three countries accounted for 48% of the total.

In the past few years, the number of AIDS deaths decreased by 20%. According to the UNAIDS report, HIV in humans is expected to end in 2015 after the popular, and "The End of AIDS 2030" in. In order to achieve this desire, the world's governments, organizations will need to work together, of course, which also lack the scientists you can not continue to engage in AIDS research.

( Bolise Co., Ltd. www.chemicalspharm.com ) 

Samsung will invest $ 740 million to build a new biological laboratories

Samsung Group's new bio-pharmaceutical Friday announced that it will spend $ 740 million to build a new plant in South Korea, after the completion of pharmaceutical production capacity can be doubled. The company is expected to be completed by 2018.

Samsung Biological Products Co., Ltd. was founded in 2011, 97 percent by Samsung Electronics Holdings, the new plant is completed, Samsung is expected to become the world's largest bio-pharmaceutical companies foundry. Currently, Samsung biological already operates a production plant, next year will build a second plant is five times as large former, and now plans to build a third annual capacity of 180,000 liters goals. New plant construction plan highlights the Samsung ambition Pharmaceutical Technology in.

Analysts said, as the slowdown in the smart phone business, Pharmaceutical Technology described under the Samsung Group has a business growth potential. Samsung said it wanted to succeed semiconductor manufacturing operations into the production of biological science and technology among.

Dilon cooperation with GE distributes its molecular breast imaging system

A bladder cancer drug clinical trials from the University of Hawaii Cancer Center has been getting closer to FDA's approval criteria, and this new drug called interleukin-15 Super antagonist compound (ALT-803) can be combined with BCG, is expected to Effective treatment of non-muscle invasive bladder cancer patients, rather than muscle invasive bladder cancer is the most common type of bladder cancer.Researchers Charles Rosser said the last time the FDA approved the drug or bladder cancer almost 20 years ago, the thing, the current bladder cancer therapy, and not much progress since the 1980s, BCG has been used for medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.Phase II clinical trials have recently been approved by the audit department and the FDA system, the first patient phase II clinical trials for the October 15, 2015 recruited, and the clinical trial will include 124 participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015 summer researchers completed the nine participants in Phase I clinical trials, at least 20% of participants expect the recurrence of bladder cancer cases will appear, but as of now, and no patients had cancer recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.

Bladder cancer will be available to fill new drugs or therapeutic drugs for 30 years blank

A bladder cancer drug clinical trials from the University of Hawaii Cancer Center has been getting closer to FDA's approval criteria, and this new drug called interleukin-15 Super antagonist compound (ALT-803) can be combined with BCG, is expected to Effective treatment of non-muscle invasive bladder cancer patients, rather than muscle invasive bladder cancer is the most common type of bladder cancer.
Researchers Charles Rosser said the last time the FDA approved the drug or bladder cancer almost 20 years ago, the thing, the current bladder cancer therapy, and not much progress since the 1980s, BCG has been used for medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.
Phase II clinical trials have recently been approved by the audit department and the FDA system, the first patient phase II clinical trials for the October 15, 2015 recruited, and the clinical trial will include 124 participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015 summer researchers completed the nine participants in Phase I clinical trials, at least 20% of participants expect the recurrence of bladder cancer cases will appear, but as of now, and no patients had cancer recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.

Scientists developed a new type of real-time detection sensor estrogen

As scientists have developed a new generation of sensors to facilitate monitoring of the patient, recently scientists from New Zealand, has also introduced a new type of sensor devices, which can help detect the body's estrogen levels, but does not carry the disadvantages of the current technology and drawbacks.
Researchers from Victoria University of Wellington, said the new sensor detects when the body's hormones, which can be screened in a lower level of liquid estrogen by sending an electrical signal, the sensor through DNA- aptamer trapping small fragments ( Aptamers) to play a role, but aptamer can "seize" the estrogen molecule, sensor devices such as transistors similar nanotubes, if the estrogen molecules are present, they would release an electrical signal.
The researchers examined the biological fluids of two lengths of such devices, one of which has 35 units long, and the other is 75 units long, found that shorter length sensor device can generate signals for mark the presence of the hormone estrogen. The longer the sensor device and does not induce an electrical signal, which may be because its surface is difficult to promote aptamer to capture estrogen molecules resulting in current. The study, published in the International Journal Journal of Vacuum Science & Technology B on.
The researchers said in a statement that this new type of sensor devices can provide an advantage in conventional screening methods, and its simple design includes a real-time reader, and consume less energy, but also with electronic monitoring system combination. The researchers next plan in a real biological fluids (such as urine) for testing the device, but the researchers also very concerned about the different applications of the technology, such as considering the use of this device is not just estrogen molecule screening.
The researchers, Professor Natalie Plank said aptamer may be a potentially powerful tool sensor, because it has a universal and selective, he believes the team will develop a final or equipment for other molecular diagnostic techniques and more application.

Last fling before the merger? Ayr build hand Rügen conduct early studies of CNS disorders

Al Construction Company and Pfizer's merger agreement finally released before Thanksgiving. However, as the history of the largest in the industry mergers and acquisitions excited when Al built the company has quietly deployed another important research and development agreement. The company will work with pharmaceutical companies to develop a series of Rugen autism, obsessive-compulsive disorder as the representative of the central nervous system disease drugs. This may be Pfizer - Al built last big action before the companies formally fit?
The company did not disclose too many details of cooperation, saying only that this cooperation includes pharmaceutical companies paid to Rugen unknown number of advances and milestone bonuses. In return, the company will be able to build Al proof of concept study phase of drug candidate molecules preferentially developed Rugen. In addition, the two sides did not disclose the same drug targets involved in the experiment. However, Al Jian said that this novel small molecule drug molecules has shown good results in animal models of autism and obsessive-compulsive disorder.
The company also said that the cooperation with Rugen company reflects its advocacy of "open science" model, which will help companies take full advantage of innovative capabilities of other academic and industrial partners. David Nicholson, executive vice president of research and development, said the company, currently in late stage clinical development of breakthrough drugs more competitive and less and less choice, so we chose the company started cooperation with Rugen development from preclinical studies aimed at the future of energy autism, OCD patients more choices.
After reaching this agreement with Pfizer built in Al announced that its $ 160 billion merger of. And with the merger of the latter it is also one of this year's entire biomedical industry's most important events. The merger is expected to be completed by mid-2016. By then, it will produce a well-deserved biopharmaceutical giant.

PMEA

Product name:PMEA
CAS:106941-25-7
Molecular Formula: C8H12N5O4P
Molecular Weight:273.19
Product description:With adenosine competitive with virus DNA, as the DNA chain termination inhibit DNA polymerase, termination of DNA synthesis, and make the viral replication is restrained, can also induce endogenous alpha interferon, increase natural killer (NK) cell activity and stimulate the body's immune response, have stronger resistance to HIV, HBV, and the role of the herpes virus.





From:  www.chemicalspharm.com/products/Herb-Extract/PMEA/
Click here to learn more: Bolise Co., Ltd.

Losartan Free Base

Product name:Losartan Free Base
CAS: 114798-26-4
Molecular Formula: C22H23ClN6O
Molecular Weight: 422.91
Product description:Light yellow solid, melting point of 183.5 ~ 183.5 ℃. PKa: 5 ~ 6.The first oral peptide angiotensin Ⅱ receptor antagonist. It is mainly used for essential hypertension.Through the direct effect of vascular smooth muscle to lower blood pressure, in blood vessel and nerve effector synaptic by reducing the indirect sympathetic output and lower blood pressure. Step-down valley/peak ratio is 60% ~ 87%

From: www.chemicalspharm.com/products/Herb-Extract/Losartan-Free-Base/
Click here to learn more: Bolise Co., Ltd. 

Dietary Guidelines can not fully believe

We all know that an ice cream sundae makes a significant rise in your blood sugar levels. But a potato or a piece of toast it? A new study found that different people on their response to food intake is completely different, this research could perhaps help physicians rethink "one size fits all" dietary advice they provide.
"Before we think of obesity and diabetes are popular because people do not follow us out of the dietary recommendations." From the Weizmann Institute of Science in Rehovot computational biologist Eran Segal said, "When you see these data Later, you might start to think that maybe the problem is that they follow our dietary recommendations. "
Current popular dietary guidelines are usually based on the most people the most healthy food to develop. "Glycemic index" is the person eating the average rise in blood sugar after a specific amount of food. Dietitians by restricting carbohydrate intake people or keep them away from high "glycemic index" foods to control diet. But carbohydrates and the glycemic index does not accurately reflect how much food for the people affected.
In order to have a better diet and metabolic understanding, Segal and his colleagues studied 800 individuals metabolism, respectively, their blood components collected, anthropometric, lifestyle and gut microbes and other information. Blood sugar fluctuations and examined participants eat meals provided by the researchers and do their own meals in a week time.
To the researchers' surprise, different people react to the same or different glucose foods are not the same, although in the same period of time the individual responses to different foods is the same. The results are published in today's Cell top. The researchers used machine learning algorithm analyzes the data, and then developed into a system to predict how people will react to different foods.
Segal and his team used these findings to develop a diet plan 26 people, these foods cause food choices are based on the minimum and maximum amount of blood sugar rises in the body. High blood sugar appreciation and many chronic diseases are related, including type 2 diabetes. The varied diet, for a person of "good" diet for another man may be "bad" diet. According to forecasts, the "good" diet can balance the body's blood sugar levels, while the "bad" diet is to make them worse.
Nobody does not realize the uniqueness of the individual metabolic systems, "we know that a few decades ago because of individual differences, people rise in blood sugar levels will be inconsistent." From Boston Children's Hospital endocrinologist and nutritionist, said David Ludwig, "This provides a quantitative data of individual differences, but the starting point is not innovative." He himself did not participate in this study.
From the University of Leeds, UK diabetes expert Eleanor Scott said she was confident this customized diet tool. And Ludwig is different, different people different her reaction to food phenomenon is not surprising, because in everyday practice, she must fight with this difference. He said the customized diet may allow patients to be more motivated to stick to it, the disease might have a huge help.
"We know that different individuals vary response to diet, we are currently in a very blunt way to deal with this issue." Scott said that through the use of physical indicators, behavior, intestinal bacteria to predict the course of people handling food, the future Doctors may have a more effective treatment of metabolic diseases.

Nature Recent research highlights

People have begun to study neurons in the hippocampus cluster, how coding and re-activate the memory, but the cortex is assumed that there are "top-down" of the input signal may affect how memory processes are relatively poorly understood. In this study, Karl Deisseroth and colleagues used new tools and strategies to identify, before from the cingulate gyrus of the hippocampus (a part of the prefrontal cortex) of a sparse projection neurons. When activated, these can lead to mice projection memory retrieval.

Scientists clarify the key mechanisms of memory formation

Researchers from the Scripps Research Institute study found, a brain protein interaction of children may have a memory to produce a significant effect, related research or for the treatment of neurodegenerative diseases develop new drugs to provide ideas; the study published in the international journal Cell, the article researchers conducted a major study of the two receptors, one of which is the neurotransmitter dopamine, which is mainly involved in learning, memory, Reward behavior, motion control, and other functions, the other one ghrelin receptors, which can be interconnected together with appetite and energy usage.
The researchers Professor Roy Smith pointed out that in an animal model study, we found that when the two receptor interactions, ghrelin receptor will change the structure of the dopamine receptor, while changing its signaling pathway, which is very important because many clinical drugs are developed based on this, such as schizophrenia, the patient compliance will be less because the reverse side effects of the performance, the study or to make use of neuronal preparations by targeting ghrelin Su indirect modification of dopamine, thereby reducing potential side effects.
Current studies or potential significance, or researchers to develop new strategies to selectively adjust the memory associated with neuronal dopamine signal, and the use of small molecules with gastric ghrelin receptor can enhance or inhibit dopamine signal ; researchers said biologically active ghrelin receptor complex will produce synaptic plasticity and ability to promote the growth and expansion of brain synapses.
Prior to the study the researchers clarify the neurons critical role in the regulation of food intake, insulin release and immune system decline in the ghrelin receptor, and this paper is to expand the importance of ghrelin receptor understanding in animal models, ghrelin receptor can inhibit and Parkinson diseases, stroke and other diseases related to neuronal loss, and perhaps this study for the treatment of late-stage development of memory deletion, targeted therapy of age-related neurological diseases provide ideas.


( Bolise Co., Ltd. www.chemicalspharm.com )

Flu vaccines are still worried about it! Maybe we'll do a better job

Each year, before the flu comes himself, to circulate, to start misinformation and misconceptions about the circulation of vaccine against influenza. Some of them contain a grain of truth, but is distorted in the end, like a secret whispered into the phone game.
But if you do not, looking for an excuse vaccine against the flu, which seems to be a persuasive argument on their own in the last year, the number of its effectiveness. Of all the measures flopped against the flu vaccine last season, clocking in at about 23 percent effective in preventing influenza infections laboratory confirmed.
But that's not the whole story, said Lisa Grohskopf, a physician in the Division of Flu Centers for Disease Control and Prevention.
"Twenty-three is better than zero, but 23 percent was complete. If you are one of those who received a strain of influenza B, it was nearly 60 percent," she said. "Even if it does not work well against a virus, there are other viruses in circulation."
Each year, the vaccine against influenza contains three (trivalent) or four (tetravalent) of influenza strains that have elected in February by the World Health Organization by the Food and Drug Administration and supported, as these experts should move in the next flu season. You select a H1N1 strain, an H3N2 strain and one strain of influenza B, or from the Yamagata lineage or Victoria Line. Tetravalent vaccines contain a B strain each line.
"The virus Yamagata-line or in the Victoria Line are quite different that there is not a lot of cross-protection," said Grohskopf. "So if we say that we have a vaccine that contains a virus family Yamagata one season, and it ends up being a predominantly Victoria season, we could not get very good protection against strains of B. "
But sometimes, experts predict is the brand, and sometimes a burden, they mutated choose before the season comes. Last year, the H3N2 strain has chosen it was a bad game, and that the tribe dominated the season, when B viruses were more frequently towards the end, Grohskopf said. Adjustments were in the vaccine against the H3N2 virus this year.
"There are certainly right, hope it'll be better this year, but it is too early to tell," said Grohskopf. "Seasons of the highly variable influenza compared to how fast they move, but now the activity is still pretty easy."
Options vaccines against influenza this year does not change much from last year, with two exceptions. The recombinant vaccine against flu virus product, and without eggs, is now (rather than just those aged 18-49) approved for all adults 18 years. And low dose intradermal vaccine against vaccine that uses a shorter needle in the skin and injects, is now available as a quadrivalent vaccine instead of only trivalent.
CDC not recommend a vaccine over another. "We really just think it's important that people are vaccinated, and depending on where you are, you may not be able to obtain a certain product," said Grohskopf. "We do not want to hunt for something and then not be vaccinated until it is too late and the flu is already high for the season."
Get vaccinated against the flu is particularly important for groups at risk and people in frequent and close contact with these risk groups Grohskopf. The most at risk of serious flu complications include pregnant women population, people aged 50 and over and children under 5 and especially under 2 years old, she said.
Anyone with a chronic illness such as lung disease, heart disease, kidney disease, liver disease, or a neurological condition also has a higher risk of serious complications from influenza infection. The most vulnerable to infection People are parents of young children, day care workers, teachers, caregivers and elderly people. In health care
But the problem with limiting influenza vaccination for these groups, she said, is that the flu bug is a tough - and unpredictable.
"While some people are definitely at a higher risk of severe illness if they get the flu even normally healthy, young - older children, young adults, most people are strong, when no other chronic diseases - can get really sick hospital, and even die, and we can not really predict who will be these people, "said Grohskopf" The majority of people who go the really ugly flu for a while and then recover without any. problem. "But even these people lose work time and the risk of the spread of the disease to family members and others, she said.
Another key to this year's additional evidence, reported that stat vaccinated against influenza every year could reduce its effectiveness in warding off the flu. This evidence is not entirely new, and scientists still do not understand, but that does not mean jumping vaccinated against influenza this year is advised if you got last year.
Meanwhile, for those who do not receive the vaccine this year, make sure it is not because one of the concerns below. As described in compounds, each of these misconceptions is based on inaccurate information, a misunderstanding or exaggeration.

Reasonable control diabetes

Diabetes management is a long-term task that requires careful planning in order to stay on top of your health.

The Centers for Disease Control and Prevention recommends:

       Take daily measurements good to eat, play sports, to inspect your feet for wounds and take your medicine.
       At each quarterly visit to the doctor, a foot examination and measurement of blood pressure.
       Twice a year, a dental examination and control of HbA1c.
       Once a year, have a cholesterol test and a test of renal function.
       Get all vaccinations recommended by doctors, including the year for flu.
       Have annual visits with a podiatrist and ophthalmologist.

( Bolise Co., Ltd. www.chemicalspharm.com ) 

FDA Approves Portrazza (panitumumab) for advanced squamous NSCLC

November 24, 2015 - The Food and Drug Administration of the United States today to treat squamous Portrazza (of necitumumab) in combination with two forms of chemotherapy in patients with advanced (metastatic) NSCLC (NSCLC) who did not receive drugs have been targeted for treatment of their advanced lung cancer.
Lung cancer is the leading cause of cancer death in the United States, with about 221.200 new diagnostics and 158.040 deaths in 2015. The most common type of lung cancer, non-small cell lung cancer, will continue in two types appointed divided main cell types found in the cancer - squamous cell carcinoma and not (which includes adenocarcinoma).
"Lung cancer can be changed so that the treatment options need to be tailored to the specific type of lung cancer patients," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for evaluation and drug research. "Today's approval provides some lung cancer patients with squamous cell a new option that can extend survival time."
Portrazza is a monoclonal antibody, usually found the activity of the EGFR, a squamous NSCLC tumor protein.
The safety and efficacy of Portrazza were evaluated in a multicenter, randomized, open clinical study with squamous NSCLC advanced 1093 participants who receive cisplatin and gemcitabine chemotherapy with or without Portrazza. Portrazza the participants and cisplatin plus gemcitabine lived longer on average (11.5 months) compared to those who do gemcitabine and cisplatin (9.9 months). Portrazza was not found to be an effective treatment for patients with non-squamous NSCLC.
The most common side effects are rash and magnesium deficiency Portrazza (hypomagnesemia), muscle weakness, seizures, may cause cardiac arrhythmia, and can be fatal. Portrazza includes a warning to health care providers more serious risks of treatment with Portrazza, including cardiac arrest and sudden death, and alert hypomagnesemia.
Portrazza is marketed by Eli Lilly and Company, Indianapolis, Indiana basis.

Novartis blockbuster mAb Cosentyx EU re two new indications!...

Swiss pharmaceutical giant Novartis (Novartis) immune pipeline industry has been concerned blockbuster monoclonal antibody drugs Cosentyx (secukimumab) harvested in the United States and Europe at the same time two major markets plaque psoriasis (plaque psoriasis) indications, the company Drug regulation in 2015 ushered in the opener. And just recently, Cosentyx EU regulation came big news again, this medicine while harvesting ankylosing spondylitis (ankylosing spondylitis, AS) and psoriatic arthritis (psoriatic arthritis, PsA) two indications.
Cosentyx is the first global interleukin-17 (IL-17) monoclonal antibody, the ratification marks the Cosentyx become IL-17 monoclonal antibody drugs in the first and only one in Europe to treat the two most common inflammatory joint diseases, but also it marks the Cosentyx become the first new treatment breakthroughs following anti-TNF monoclonal antibody drugs for 16 years after the listing of AS clinical regard.
According to recently published data, Cosentyx in 1-3 weeks of treatment can significantly improve the AS or PsA signs and symptoms, and this improvement can be sustained for more than 2 years. AS aspect, Cosentyx patients receiving treatment, up to 80% at 2 years after the adoption of X-ray inspection showed no progress in spinal cord injury; PsA regard Cosentyx patients receiving treatment, up to 84% at 2 years after the adoption of X-ray inspection showed no joint damage progression.
Currently, in clinical trials across multiple indications aspects, there are more than 9600 cases of patients received Cosentyx treatment; there are more than 12,500 cases of patients underwent post-marketing studies Cosentyx treatment. Safety, Cosentyx consistent performance in clinical research across multiple indications in.
Specifically, AS aspect, Cosentyx EU approved for adult patients with AS conventional therapies (such as non-steroidal anti-inflammatory drugs) inadequate response; PsA aspect, Cosentyx EU approved as a single agent or in combination with methotrexate (methotrexate) for the previous disease-modifying anti-rheumatic drug reactions against inadequate PsA in adult patients.
In addition, Novartis is also actively promoting other relevant clinical program Cosentyx, and expanding the potential indications for the drug. Cosentyx of the industry is very optimistic about business prospects, expected annual sales of the drug to 2020 will exceed $ 1 billion, becoming the IL-17 mAb heavy field a shining star.
However, the other competitors in the field are quickly follow, such as Lilly's IL-17 mAb ixekizumab in a number of Phase III clinical also set a remarkable achievement.
Another noteworthy event was the British pharmaceutical giant AstraZeneca has also been high hopes for the industry before the IL-17 mAb brodalumab, but brodalumab patients treated in clinical trials observed suicidal tendencies, Amgen select AstraZeneca parted ways; and AstraZeneca chose to give up more than three months after reflection after brodalumab price of $ 445 million will be packaged for sale to Valeant Pharmaceuticals, the event is also the industry that AstraZeneca in inflammatory diseases A flaw field.

BGI strategic realignment of the US subsidiary of a large-scale layoffs

Complete Genomics is a California-based gene sequencing company, in September 2012 was due to the $ 117 million BGI acquisition. According to the outgoing Complete Genomics CEO Cliff Reid (Cliff Reid), said Wang Jun resigned this summer after BGI CEO, the company began to reassess business strategies.
Today, BGI decided to become a subsidiary of Complete Genomics Genomics R & D center, the business center of gravity is no longer provided Revolocity gene sequencer. Complete Genomics June this year released Revolocity, the system is priced at $ 12 million, to be completed by 10,000 whole genome sequencing year.
So far, Revolocity won three customer orders, planned deliveries in the first half of next year. But Reid has said, now BGI after strategic adjustments, Complete Genomics is no longer accepted Revolocity orders. As for the previous three customers, we must delay delivery.
After the strategic adjustment, Complete Genomics will become a research and development center BGI to support products and clinical trials BGI. Complete Genomics has about 200 employees, Reid did not disclose how many employees will be affected.

( Bolise Co., Ltd. www.chemicalspharm.com )

Chinese scientists found that prostate cancer-specific methylation sites

Prostate cancer is the most common male malignancy, the current traditional diagnostic methods for prostate cancer is serum-specific antigen (PSA) concentrations were higher in patients with PSA biopsy final diagnosis.
However, the main disadvantage of this method is poor specificity of PSA (PSA 4-10ng / ml, the specificity of only 25% -40%), other issues such as prostatitis, benign prostatic hyperplasia and other prostate disease can also cause abnormal PSA concentration , it will often unnecessary biopsy to patients caused great suffering. Therefore, an urgent need to find a sensitive and specific early diagnostic marker for prostate cancer.
Recently, the Beijing Genomics Institute, Chinese Academy of Sciences Laboratory of Genomic Medicine precision Sun Yingli group in cooperation with the Shanghai Second Military Medical University, Changhai Hospital, through the Y chromosome methylation analysis and comparison of 66 pairs of prostate cancer and paraneoplastic samples, found prostate cancer in specific methylation sites.
The study by side comparison of cancer methylation levels between samples, found some relatively conservative methylation sites on the Y chromosome, which in methylation levels between different individuals is almost the same, regardless of age and geographical Effect of other factors, but these relatively conservative paracancerous sample methylation sites in cancer samples has undergone a significant variation in methylation, and screened a total of six conserved in paraneoplastic and in cancer Changes in specific sites.
After further DNA testing to verify the urine, the researchers finally selected a specific methylation sites. Its receiver characteristic curve (ROC) analysis showed that the site of prostate cancer diagnosis sensitivity and specificity were 94.6% and reached 78.3%, far superior to the traditional PSA method, and the method is to detect through urine samples, are a non-invasive means of non-invasive detection of liquid.
Liquid biopsy is currently the non-invasive diagnostic research focus has broad application prospects, is an inevitable trend in the future development of molecular diagnostic techniques. DNA methylation detection with strong tissue specificity, and therefore has a unique advantage in liquid biopsy applications, will become cancer diagnosis, prognosis and an important means of detecting treatment.
At present, domestic and international differences in DNA methylation in the urine for the diagnosis of prostate cancer is still blank, so the study leading level. In related research Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer in the title published in the journal oncotarget. The study was Ministry of Science and Basic Research Program of China (973), strategic pilot projects funded Chinese Academy of Sciences, National Natural Science Foundation and other projects.

( Bolise Co., Ltd. www.chemicalspharm.com )

Four Gilead HIV approved new drug Genvoya eligible for Europe, effective, and more secure

Gilead is the absolute leader in the field of AIDS treatment, the company developed the drug Four Stribild (E / C / F / TDF) in 2012 and 2013 have been listed in the United States and Europe the second largest market, greatly simplifying HIV The treatment procedures. This month, the newly developed Four Gilead HIV DRUG Genvoya (E / C / F / TAF) in the United States and the EU regulation have been big news came: the 5th of this month, Genvoya obtain FDA approval; on the 23rd of this month , Genvoya re-approved by the EU:
- The United States, Genvoya crowd is: never received treatment HIV-1 infected adults, aged 12 and older weighing at least 35 kilograms of HIV-1 infection among adolescents, as well as HIV-1 virus is currently being inhibited HIV- 1 adult infection.- EU, Genvoya crowd as: HIV-1 infected adults, aged 12 and older weighing at least 35 kilograms of adolescent HIV-1 infection, the condition does not exist and integrase inhibitors emtricitabine or tenofovir Wei mutations associated with resistance to any.
In clinical trials, Genvoya (E / C / F / TAF) comparable efficacy Stribild (E / C / F / TDF), while improving kidney and skeletal parameters, higher security, a wider application of the crowd, the drug will become Gilead HIV franchise in another Reggie, is a new gospel of global HIV community.

Drug sales, the fawn male or female?

EC pharmaceutical sales strategy emphasizes, must be firmly fixed on the female consumer groups, firmly grasp their wallets, because they control the family purse strings.
However, the media recently named by ID Media's survey found that men also have demand to buy drugs, and medical decisions in the family, men play a more active role. ID Media, according to data collected show, when faced with drug ads or health-related information, the male is superior to women in many aspects.
Although compared with men, women buy a larger proportion of prescription drugs --52% VS35%, but men pay more attention to drug sales and related information.
For example, 68% of men believe they have a responsibility to understand the doctor's prescription, while only 60 percent of the female population have this consciousness. In addition, 54% of men said that when they decide what to buy medicines, will get valuable advice from the drug information, while only 47 percent of women have this experience. Buy prescription drugs, consumer groups, 48% of men will study prescription drug information on its Web site, while only 37 percent of women said they would do so.
Senior director of media strategy at ID Media's Michael Baliber said that advances in technology prompted men and women through the Internet relevant medical information, especially mobile universal client, making men more access to the medical information, and participate in decision-making.
The study also revealed differences between men of different ages in the drug buy respect. There is no doubt that men aged 18-34 than in men 35-64 years of age are more easily accepted drug sales and related information. Male 18-34 age group, 41% said they were to focus on the development of new drugs and medical information through TV, print and online advertising, while in the male population in the 35-64 age group, the rate is only It is 23%. In addition, young people represent drug advertising will encourage them to consult a physician drug-related information, and the previous generation of the population, only 22 percent have this habit.
Interestingly, 71% of the previous generation of the crowd, said to the doctor to understand the knowledge of prescription drugs is their responsibility, while only 63% of young people think so.
These data illustrate what? This is the ID Media next research plan. They will be carried out to test for digital media men and women, and different groups of men.
In any case, this survey suggests that pharmaceutical sales department to change the stereotype, based on the new features of technology and social development to adjust the marketing strategy.

Amgen fell by NICE for Repatha said no!

In the latest NICE guidance published in, Repatha failed to get praise managers. The reason for this is due to two things. First, the existing data from clinical studies failed to demonstrate its efficacy. Although Repatha in reducing bad cholesterol remarkable achievements, but there is no evidence that these cholesterol levels by lowering the risk of the user can reduce angina, heart disease.
In addition, some analytical methods Repatha NICE also been questioned, for example, in the study Amgen researchers used the Framingham assessment criteria rather than NICE recommended to analyze the efficacy of the drug. Therefore, managers also need to wait until the second half of 2016 in order to lower the effect of conclusion. Secondly, PCSK9 drugs a listing of its high price, let everyone stunned. Patients need to pay £ 4,448.60 (140mg receiving treatment every two weeks) or £ 6,123.60 (420mg receiving monthly treatment), the high price for NICE unacceptable.
In fact, PCSK9 price issue has so many people criticized. Whether Repatha or Sanofi / regeneration yuan's Repatha are so patient and kind of health insurance companies to be "robbed" feeling. In the US, the pricing of these two drugs were $ 14,100 / year and $ 14,600 / year. The estimated non-profit organization Institute for Clinical and Economic Review, the reasonable price range of these two drugs should be between $ 3,615- $ 4,811.
Although Amgen is working with various aspects Repatha approached in terms of price, but it is clear that companies also need to show more sincerity.

( Bolise Co., Ltd. www.chemicalspharm.com )

Once contraception for 5 years! Bayer submitted a listing application of long-term intrauterine device

German pharmaceutical giant Bayer (Bayer) today announced that the European Union and the United States has been submitted to regulators listing application of new long-acting intrauterine device LCS-16, which is a new low-dose levonorgestrel releasing intrauterine system (LNG-IUS), placed directly in the uterus, can provide up to 5 years of contraception. LNG-IUS is one of the most effective long-term contraceptive methods, can be removed at any time, after removing the women can quickly return to normal fertility.
LCS-16 is a small flexible plastic T-shaped device, once placed in the uterus, can release a low dose of progestin levonorgestrel, can provide up to 5 years of contraception. LCS-16 after removal, women can quickly return to normal fertility.
Phase III clinical program LCS-16, involving countries from North America and Europe, 574 cases of nulliparous (nulliparous) and 878 cases of maternal (parous), the primary endpoint of the clinical program for the introduction of Pearl Index (Pearl Index, PI) Evaluation The contraceptive effect. Data show that, LCS-16 contraceptive efficiency of over 98.5%, 3-year Pearl index was 0.31, 5-year Pearl index was 0.29. Study, LCS-16 overall well tolerated, unexpected adverse events occurred.
In April this year, generics giant Actavis (Actavis) in the United States launched a new intrauterine drug delivery device (IUD) Liletta, placed into the uterus after, can provide up to three years of contraception. In IUS study in Phase III ACCESS, Liletta duration of three years effective contraception up to 99.45%, after using the body mass index and women (BMI) no significant change. Currently, the study continues to evaluate Liletta use up to four years, five years, seven years of contraceptive efficacy and safety.

( Bolise Co., Ltd. www.chemicalspharm.com )

$ 150 billion! The pharmaceutical industry's largest merger finalized!

Pfizer to $ 150 billion takeover deal finally reached El build, he is expected to sign the approval of the boards of both companies on Sunday. It will also become the pharmaceutical industry's largest merger.
According to Friday's closing price of Pfizer, Ayr build than October 28 closing price of 27% of the premium. Pfizer and Al ratio of convertible plans to build 11.3: 1. The deal also involves a small portion of cash, accounts for less than 10% of the transaction price.
The acquisition of small and large, the American company Pfizer headquarters to pave the way for Ireland to achieve revenue upside (US tax rate of 35%, the Irish tax rate of 12.5%). However, in view of the transaction created the largest ever recorded medical industry, but also coincides with a key moment in American presidential election, it will inevitably lead to some controversy. In addition, Al Jian CEO Brent Saunders has caused controversy in the research and development of pharmaceutical companies. He specializes in asset transactions, corporate internal drug development skepticism future strategy after joining the new company may be subject to change.
Informed sources said Pfizer CEO Ian Read will serve as CEO of the new company, Al-built CEO Brent Saunders will serve a very senior position in the company's operations and integration, and also in the combined The Board of Directors take place.
The transaction would create an annual sales exceeding $ 60 billion pharmaceutical giant, the combined group will be ahead of the second largest US pharmaceutical companies Merck (Merck & Co), which generated sales of $ 40 billion.

( Bolise Co., Ltd. www.chemicalspharm.com )

Genentech, Novartis, Ophthotech jointly develop three rows | broad prospects drugs pegpleranib

With the popularity of computers and mobile phones, people are spending more and more time to spend in the electrical equipment. However, for a long time watching the screen also allows the eye overwhelmed. In recent years, eye disease patient population size has been a growing trend. Therefore, more and more companies began to strengthen in the biomedical aspects of eye disease research, especially with the age-related eye diseases.
Roche's Genentech recently announced that it would invest Ophthotech company for the treatment of age-related macular degeneration (AMD) new drug Pegpleranib, and will be another pharmaceutical giant Novartis share this medicine overseas copyright.
Is sought after the two giants pegpleranib is currently in two Phase III clinical studies. Researchers are evaluated on the drug and Genentech's Lucentis combined with the effect. Pegpleranib is an anti-platelet-derived growth factor, can prevent blood vessels associated with AMD mistake growth. The Lucentis is a vascular endothelial growth factor inhibitor drugs. Ophthotech company believes this two drugs can play a good synergy in AMD treatment. Two clinical studies expected to be completed in the fourth quarter of 2017. In addition, the company will phase III clinical study with Roche's Avastin Eylea pegpleranib and regeneration of dollars and will be combined with.
As early as in 2014, Novartis and Ophthotech company seeking to develop the drug reached a cooperation agreement. Novartis to Ophthotech company paid $ 200 million in advances and milestones of up to $ 800 million in prize money. On the other hand, Novartis added for Genentech surely welcomed. Since early in 2003, Novartis gained the right to sell Lucentis outside the US from Genentech aspect, so this will also join the Genentech makes tripartite more smoothly in the drug development.

( Bolise Co., Ltd. www.chemicalspharm.com )